Back to Authors

Foltynie, Thomas

0000-0003-0752-1813

Mayo Clinic

National Hospital for Neurology and Neurosurgery

Citations 3

FAT1 weighted MRI: Diffusion meets anatomical imaging and application in thalamic surgery for tremor
Goedemans, Taco , Ferreira, Francisca , Wirth, Thomas , Weerd, Lonneke van der, Massey, Flavia V. , Krüger, Marie T., Milanese, Vanessa, Pakzad, Ashkan , Limousin, Patricia , Bot, Maarten , Schuurman, Rick , Foltynie, Thomas , Munckhof, Pepijn van den , Zrinzo, Ludvic , Akram, Harith

Imaging Neuroscience | April 5, 2024 | Volume: 2 | Issue: No issue available | Pages: No page available

10.1162/imag_a_00139 Get It

Abstract Patient-specific targeting of the Ventral intermediate nucleus (Vim) of the thalamus can be achieved with MR connectivity. Nevertheless, there are several drawbacks to using tractography-based targeting methods to visualise distinct thalamic nuclei (e.g., subjective region of interest selection, and thresholding of resulting tracts and clusters). Fractional anisotropy (FA) mapping, another product of diffusion MRI (dMRI), does not rely on tractography, and could thus be clinically more viable for discerning thalamic anatomy for stereotactic surgery. The aim of this study is to develop and present a hybrid, high-resolution, and high-fidelity imaging modality that combines contrast from FA maps as well as anatomical T1 sequences (FAT1 imaging); and to evaluate FAT1 based Vim-target definition. Imaging and outcome data of 35 consecutive refractory tremor patients who had undergone 43 connectivity guided deep brain stimulation (DBS) and/or radiofrequency thermocoagulation (RF-T) between 2013 and 2021 were included. First, the pre-operatively acquired dMRI and MPRAGE sequences were used to create FAT1 maps in retrospect. Then, an FAT1 based Vim-target was planned by an experienced functional neurosurgeon who was blinded for patient outcome. Finally, to investigate FAT1 based targeting, a post-hoc analysis was carried out of the degree of overlap between the newly created FAT1 based Vim-target, and the volume of tissue activation (VTA, in case of DBS) or lesion volume (in case of RF-T). This degree of overlap was compared between favourable and unfavourable outcome groups: outcomes were measured by experts blinded for imaging data at the last follow-up using a Clinical Global Impression-Improvement score (CGI-I), where a CGI-I score of 1-2 (i.e., FTMTRS improvement of ≥50%) was considered favourable. In 36 of the 43 (84%) performed surgeries (24 DBS and 19 RF-T), FAT1 based Vim-targeting was possible. For the group showing favourable outcome (71% of the patients at a median follow-up of 13 months), the mean amount of overlap between the FAT1 based Vim-target and the VTA or lesion was 42% (±13), versus 17% (±15) for patients with an unfavourable outcome (MD 25%, 95% CI 14–35, p < 0.0001). Retrospective use of FAT1 based Vim-targeting as a tool to predict outcome had a sensitivity of 90%, specificity of 80%, positive predictive value of 90%, and negative predictive value of 80%. In conclusion, FAT1 imaging is a new, high-resolution, and high-fidelity modality that combines diffusion and anatomical MRI. It provides a fast and efficacious way of targeting the ventral intermediate nucleus of the thalamus. In this study, FAT1 based targeting was highly accurate in predicting outcomes after deep brain stimulation and radiofrequency thalamotomy.
Tourette syndrome deep brain stimulation: A review and updated recommendations
Schrock, Lauren E. , Woods, Douglas W. , Porta, Mauro, Servello, Domenico , Silburn, Peter A., Walker, Harrison C. , Shahed‐Jimenez, Joohi, Savica, Rodolfo , Klassen, Bryan T. , Foote, Kelly D. , Ackermans, Linda , Temel, Yasin , Changizi, Barbara Kelly , Lozano, Andrés M. , Auyeung, M., Kaido, Takanobu, Agid, Yves, Welter, Marie Laure, Khandhar, Suketu M., Pourfar, Michael , Walter, Benjamin L. , Juncos, Jorge L., Leckman, James F. , Neimat, Joseph A, Okun, Michael S. , Jimenez‐Shahed, Joohi , Mink, Jonathan W. , Visser-Vandewalle, Veerle E. R. M. , Foltynie, Thomas , Machado, André G. , Zhang, Jianguo , Hu, Wei , Mari, Zoltan K. , Auyeung, Man , Mogilner, Alon Y. , Gross, Robert E. , Kuhn, Jens , Okun, Michael S , Leckman, James F , Walter, Benjamin L , Jimenez-Shahed, Joohi , Welter, Marie‐Laure

Movement Disorders | December 8, 2014 | Volume: 30 | Issue: 4 | Pages: 448-471

10.1002/mds.26094 Get It

Abstract Deep brain stimulation (DBS) may improve disabling tics in severely affected medication and behaviorally resistant Tourette syndrome (TS). Here we review all reported cases of TS DBS and provide updated recommendations for selection, assessment, and management of potential TS DBS cases based on the literature and implantation experience. Candidates should have a Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition (DSM V) diagnosis of TS with severe motor and vocal tics, which despite exhaustive medical and behavioral treatment trials result in significant impairment. Deep brain stimulation should be offered to patients only by experienced DBS centers after evaluation by a multidisciplinary team. Rigorous preoperative and postoperative outcome measures of tics and associated comorbidities should be used. Tics and comorbid neuropsychiatric conditions should be optimally treated per current expert standards, and tics should be the major cause of disability. Psychogenic tics, embellishment, and malingering should be recognized and addressed. We have removed the previously suggested 25‐year‐old age limit, with the specification that a multidisciplinary team approach for screening is employed. A local ethics committee or institutional review board should be consulted for consideration of cases involving persons younger than 18 years of age, as well as in cases with urgent indications. Tourette syndrome patients represent a unique and complex population, and studies reveal a higher risk for post‐DBS complications. Successes and failures have been reported for multiple brain targets; however, the optimal surgical approach remains unknown. Tourette syndrome DBS, though still evolving, is a promising approach for a subset of medication refractory and severely affected patients. © 2014 International Parkinson and Movement Disorder Society